While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...
The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...
The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...
Energy and marine consultancy ABL has secured new five-year contracts with long-term client Woodside Energy that expands its existing workscope outside of Australia. ABL has been awarded a global ...
Shenzhen Targetrx Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a Bcr-Abl (Bcr-Abl1) kinase and its mutant ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The Phase III trial, testing the drug in patients whose cancers are Philadelphia chromosome-positive, will expand to the US and Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback